Abbvie M24-885 An Open Label Treatment Study for Adults with Moderate to Severe Crohn’s Disease
- Study HIC#:2000038209
- Last Updated:11/19/2025
The purpose of this study is to test the safety and effectiveness of Risankizumab, Lutikizumab and ABBV-382 for the treatment of adults with moderately to severely active Crohn’s Disease.
Contact Us
For more information about this study, including how to volunteer, contact:
Elizabeth Ruggiero
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The objective is to evaluate the safety and efficacy and to assess the mechanistic profile of studied monotherapy and combination therapy TaTs when compared to the common comparator arm.
Eligibility Criteria
Adults 18-75 years of age with a confirmed diagnosis of Crohn’s Disease for at least 3 months who are willing and able to sign a consent form. They must have tried at least one treatment previously. Must be having symptoms of Crohn’s Disease but deemed to be in overall general good health.
